Tue, Jul 29, 2014, 6:09 AM EDT - U.S. Markets open in 3 hrs 21 mins


% | $
Click the to save as a favorite.

RXi Pharmaceuticals Corporation Message Board

rmsacc 294 posts  |  Last Activity: 15 hours ago Member since: Apr 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "An illegal practice whereby two or more market makers collectively attempt to influence and change the price of a stock. Ghosting is used by corrupt companies to affect stock prices so they can profit from the price movement."

    An unfortunate result of market makers being given the ability to trade in the very stocks that they make markets for. You can thank the SEC for it............

  • rmsacc rmsacc Jun 13, 2014 11:06 AM Flag

    Well soon give the definitions to more manipulative tactics you guys use hedge, such as bear raiding, wash trading, runs, pools, etc.

    Will keep you posted....

  • Obviously avimoron, you are unaware of the long string of successes that Dr, Cauwenbergh has under his belt. Now with an even greater prospect with a "platform" technology allowing myriad partnering and licensing possibilities, I would say RXI's chances of success are very good.

    It appears that you do not know much about the company and its human elements, and your comments are merely generic.

    But hey, your a paid stock basher. You have only one agenda.................

    Every once in a while I take you guys off ignore just to expose you and to have a good laugh......

  • He lurks in the background following every word of every post of the stocks that he follows. Notice his attempts at belittling posters for their lack of market knowledge.

    Why does he scour the boards so attentively? Good question is it not? He neither follows nor mentions the science, management, or potential. He has no interest in RXI as a company, only as feeding grounds for hm and his miscreant associates.

    His goal is solely to capitalize on creating fear among investors. He is not at all interested in RXI, he is only interested in preying on weak hands.

    He is a very slippery stock manipulator.

    It makes him highly disliked by all but one poster who frequents here. But this does not prevent him from his mission; untruths and deceit. the very one thing he lacks, integrity.


  • Reply to

    James Skalko

    by avl.morax Jun 23, 2014 11:11 AM
    rmsacc rmsacc Jun 23, 2014 2:46 PM Flag

    You do enjoy talking down to people don't you. I suppose that's why nobody likes you, that is except for one perhaps.

    Looks like you just ask for me to expose you for the miscreant that you are. I shall post some of your more memorable comments when I get the time.

    See folks he goes crazy when I expose his motives. Criminals do not like attention....................Good luck all

  • Reply to

    Email from Tamara for RXII

    by biotechpicklist Jul 25, 2014 8:23 PM
    rmsacc rmsacc Jul 25, 2014 10:37 PM Flag

    bio, as always many thanks. Your input most valuable. GLTA

  • His direct quotes from previous responses to me ;

    1. quote: "altruism and to share ideas with fellow investors. How's that? Satiate your need to "know?"
    2. quote: "What if I said I like to translate thoughts into words and this is my canvas?"
    3. quote: " I am only here to help you."

    Personally I like #3.

    Good luck All

  • Mr. White joined Laidlaw & Company Ltd. in June 2012 with over 16 years of Wall Street healthcare analyst experience. Prior to Laidlaw, he was the Senior Med Tech Equity Analyst (sellside) at Murphy & Durieu, an investment bank and NYSE member founded in 1929. While at Murphy & Durieu, Mr. White was recognized by StarMine as one of the top medical device analysts for accuracy of earnings estimates. He was the Senior Healthcare Analyst (buyside) at Mitsubishi UFJ Trust and Management (MUFG) for 6 ½ years before his time at Murphy. Mr. White generated ideas and managed healthcare equity investments for many funds at Mitsubishi including the primary ex-Japan fund, which at its peak held over $16 billion in equity assets including over $1.3 billion in US Healthcare equity holdings for which Mr. White was responsible. Prior to Mitsubishi, Mr. White was a sell-side analyst for 7 years. Over almost five years, he worked on two (Major Pharmaceuticals and Managed Care) Institutional Investor ranked sell-side equity teams at Deutsche Bank Securities. Prior to Deutsche Bank, Mr. White worked as a sell-side healthcare analyst at Gerard, Klauer Mattison & Company (now BMO Capital Markets) and Fahnestock & Company (now Oppenheimer & Co.). Mr. White graduated from Manhattan College with a B.S. in Biology and attended Mount Sinai School of Medicine for 2 ½ years. He received an M.B.A. in Finance from Rensselaer Polytechnic Institute. Mr. White holds the following security industry licenses: Series 7, 63, 86 and 87.

  • Reply to

    hedgehog: "the big shot"

    by avl.morax Jul 10, 2014 2:01 PM
    rmsacc rmsacc Jul 10, 2014 2:31 PM Flag

    A legend in his own mind...........................

  • due to quickness of skin healing and readily visible external results benefit those in the know. As opposed to internal compounds such as those in cancer trials which take years to complete, Rxi-109 trials take months, as we witnessed in p1. Scheduled for completion early 2015 with interim update promised mid 2014, my guess is that biotech investors are simply not aware of how quickly RXI could advance, hence the current share price perhaps.

    Just a thought this morning............GLTA

  • The name of RXI's new patent granted just a couple weeks ago. A rewind refresher and follow up on golong's post from yesterday;

    This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd‑rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle. sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

    "We are pleased to have our novel technology recognized by the United States Patent and Trademark Office," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This key patent is what differentiates RXi's technology platform from the competition. It provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles, which are commonly used with the other siRNcompounds in clinical development. The use of our proprietary sd‑rxRNA technology platform may lead to improved tolerability and thereby potentially broadening of the therapeutic window for these compounds."

    Yes hedge, cut and paste for dummies.....

  • Reply to

    Nuttin but crickets

    by celltones Jul 12, 2014 10:27 PM
    rmsacc rmsacc Jul 13, 2014 8:03 AM Flag

    Brilliant comment, such depth of reasoning. How can we ever thank you?

  • Reply to

    To avimoron, "the idiot" stock basher....

    by rmsacc Jun 12, 2014 10:48 AM
    rmsacc rmsacc Jun 12, 2014 12:26 PM Flag

    Can't you paid stock bashers control your anger? This is a public forum hedhrlks. Screaming in capital letter yet, telling me to "shut my mouth", how childish.

  • And in charge of RXI's opthalmology development. Sr. devlp director of Sirna from 2002-2006 when Sirna was purchased by Merck for $1.1B.

    She also managed Sirna's partnership with Allergan, A company who I feel will be very interested in today's news. It is right up their alley.

    Big pharma is on the hunt to add to their pipelines. They are buying rather than developing in house. Just look at all the Pharma deals past few weeks. Just today Astra Zeneca turned down a $106.5 billion (yes you read that correctly) from Pfizer.

    Dr. Cauwenbergh keeps putting one foot before the other, A master of creating value.....good luck All

  • Reply to


    by hedgerisklies May 21, 2014 4:32 PM
    rmsacc rmsacc May 21, 2014 5:16 PM Flag

    Not me hedge, but I did like his message...............

  • rmsacc rmsacc Jun 24, 2014 5:23 PM Flag

    Most here do not trade in the stock of $40m market cap experimental biotech stocks hanna. Personally I think its crazy. There is no action here at present.

    I like the science, the expanded IP, and especially the management. I"m in for long term. I have a very good feeling that the good Doctor has something in store..................good luck All

  • Can't say I'm surprised, after all you are all idiot MM lackeys working for day wages. We don't hate you for it, Its your job. Its just a stinking job, if you know what I mean..................

  • Keep your eye on the science. It is all that matters. Cauwenbergh is the deciding factor with this little company.

    Now, I'll go have a good cry. Lost to Belgium, Oh No..........good luck All.

  • Message sent IR;

    Dear Ms. McGrillen; If you get the chance kindly let me know who Dr. Cauwenbergh is rooting for in today's USA Belgium match.

    Thanks, hope all's well.....

  • Reply to

    To avimoron, "the idiot" stock basher....

    by rmsacc Jun 12, 2014 10:48 AM
    rmsacc rmsacc Jun 12, 2014 5:07 PM Flag

    hedge, if you have a soft spot for avi that's fine. But why not come clean; Most on this board know you are here to create fear and to test the resolve of honest retail investors to entice them into selling shares. Those that are not privy to your savvy methods, like hanna for instance.

    I will keep on exposing you for the miscreant that you are for the benefit of some unaware of your motives, and the motives of blobbish and axmoron, your cohorts in crime.........

    These people are not your friends folks, remember that...................

2.50+0.02(+0.81%)Jul 28 3:58 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.